177 related articles for article (PubMed ID: 25655855)
1. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
Taçoy G; Çengel A; Özkurt ZN; Türkoğlu S
Turk Kardiyol Dern Ars; 2015 Jan; 43(1):78-81. PubMed ID: 25655855
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
4. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
[No Abstract] [Full Text] [Related]
5. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
6. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
Kim JC; Shin SH; Yi HG; Kim SH; Woo SI; Kim DH; Park KS; Kwan J
Herz; 2013 Dec; 38(8):931-3. PubMed ID: 23430094
[No Abstract] [Full Text] [Related]
7. Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia.
Ohta S; Najima Y; Imamura J
Br J Haematol; 2015 Jun; 169(5):612. PubMed ID: 25855138
[No Abstract] [Full Text] [Related]
8. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
[TBL] [Abstract][Full Text] [Related]
9. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
10. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
Liu B; Wang Y; Mi Y; Wang J
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):581-6. PubMed ID: 25052596
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
Chang H; Hung YS; Chou WC
Int J Infect Dis; 2014 Aug; 25():165-7. PubMed ID: 24932855
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib.
Lindauer M; Hochhaus A
Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
[TBL] [Abstract][Full Text] [Related]
13. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
Wang HC; Lee CS; Liu TC
Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
[No Abstract] [Full Text] [Related]
14. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
15. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
Rasheed W; Flaim B; Seymour JF
Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
[No Abstract] [Full Text] [Related]
16. Dasatinib: BMS 354825.
Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
[TBL] [Abstract][Full Text] [Related]
19. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
[No Abstract] [Full Text] [Related]
20. Reversible pre-capillary pulmonary hypertension due to dasatinib.
Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
